ArticleClinical & translational immunology2021
Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2.
Open access · goldAbstract read
In one paragraph
Article in Clinical & translational immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 61 citations in OpenAlex.
- Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18-55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial.The Journal of infectious diseases · 2026Trial
- Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients.Frontiers in immunology · 2025Trial
- Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.The Lancet. Infectious diseases · 2021Trial
- Optoelectronic Tweezers for Single-Cell Research: Principles, Applications, and Prospects.Cyborg and bionic systems (Washington, D.C.) · 2026Review
- A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirus.PLoS pathogens · 2025Article
- Modifying the glycosylation profile of SARS-CoV-2 spike-based subunit vaccines alters focusing of the humoral immune response in a mouse model.Communications medicine · 2025Article
- Skin patch delivery of a SARS-CoV-2 spike DNA vaccine produces broad neutralising antibody responses.Heliyon · 2025Article
- Review
- Dynamin independent endocytosis is an alternative cell entry mechanism for multiple animal viruses.PLoS pathogens · 2024Article
- The role of N-glycosylation in spike antigenicity for the SARS-CoV-2 gamma variant.Glycobiology · 2024Article
- Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages.Nature communications · 2024Article
- Prefusion stabilization of the Hendra and Langya virus F proteins.Journal of virology · 2024Article
- The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2.ACS omega · 2024Review
- Structure and antigenicity of divergent Henipavirus fusion glycoproteins.Nature communications · 2023Article
- Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress.International journal of molecular sciences · 2023Review
- Two formulations of coronavirus disease-19 recombinant subunit vaccine candidate made up of S1 fragment protein P1, S2 fragment protein P2, and nucleocapsid protein elicit strong immunogenicity in mice.Immunity, inflammation and disease · 2022Article
- Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations.Journal of drug delivery science and technology · 2022Review
- Protein engineering responses to the COVID-19 pandemic.Current opinion in structural biology · 2022Review
- Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity.International journal of molecular sciences · 2022Article
- Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors at 7 institutions in 3 countries.
Daniel WattersonSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Danushka K WijesundaraSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Naphak ModhiranSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Francesca L MordantDepartment of Microbiology and Immunology The University of Melbourne Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.ORCID https://orcid.org/0000-0002-3754-2642
Zheyi LiDepartment of Immunology and Infectious Disease The John Curtin School of Medical Research, The Australian National University Canberra ACT Australia.
Michael S AvumegahSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Christopher Ld McMillanSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Julia LackenbySchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Kate GuilfoyleViroclinics Xplore Schaijk The Netherlands.
Geert van AmerongenViroclinics Xplore Schaijk The Netherlands.
Koert StittelaarViroclinics Xplore Schaijk The Netherlands.
Stacey Tm CheungSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Summa BibbySchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Mallory DalerisThe Australian Institute for Bioengineering and Nanotechnology The University of Queensland St Lucia QLD Australia.
Kym HogerThe Australian Institute for Bioengineering and Nanotechnology The University of Queensland St Lucia QLD Australia.
Marianne GillardThe Australian Institute for Bioengineering and Nanotechnology The University of Queensland St Lucia QLD Australia.
Eve RadunzThe Australian Institute for Bioengineering and Nanotechnology The University of Queensland St Lucia QLD Australia.ORCID https://orcid.org/0000-0002-4734-2898
Martina L JonesThe Australian Institute for Bioengineering and Nanotechnology The University of Queensland St Lucia QLD Australia.ORCID https://orcid.org/0000-0002-5154-6017
Karen HughesThe Australian Institute for Bioengineering and Nanotechnology The University of Queensland St Lucia QLD Australia.
Ben HughesThe Australian Institute for Bioengineering and Nanotechnology The University of Queensland St Lucia QLD Australia.
Justin GohThe Australian Institute for Bioengineering and Nanotechnology The University of Queensland St Lucia QLD Australia.
David EdwardsThe Australian Institute for Bioengineering and Nanotechnology The University of Queensland St Lucia QLD Australia.
Judith ScobleCSIRO Manufacturing Parkville VIC Australia.
Lesley PearceCSIRO Manufacturing Parkville VIC Australia.
Lukasz KowalczykCSIRO Manufacturing Parkville VIC Australia.
Tram PhanCSIRO Manufacturing Parkville VIC Australia.
Mylinh LaCSIRO Manufacturing Parkville VIC Australia.
Louis LuCSIRO Manufacturing Parkville VIC Australia.
Tam PhamCSIRO Manufacturing Parkville VIC Australia.
Qi ZhouCSIRO Manufacturing Parkville VIC Australia.
David A BrockmanTetraQ The University of Queensland St Lucia QLD Australia.
Sherry J MorganStageBio Mason OH USA.
Cora LauUniversity of Queensland Biological Resources The University of Queensland St Lucia QLD Australia.
Mai H TranTetraQ The University of Queensland St Lucia QLD Australia.
Peter TapleyTetraQ The University of Queensland St Lucia QLD Australia.
Fernando Villalón-LetelierDepartment of Microbiology and Immunology The University of Melbourne Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
James BarnesWHO Collaborating Centre for Reference and Research on Influenza Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
Andrew YoungSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Noushin JaberolansarSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Connor Ap ScottSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Ariel IsaacsSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Alberto A AmarillaSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Alexander A KhromykhSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Judith Ma van den BrandDivision of Pathology Faculty of Veterinary Medicine Utrecht University Utrecht The Netherlands.
Patrick C ReadingDepartment of Microbiology and Immunology The University of Melbourne Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
Charani RanasingheDepartment of Immunology and Infectious Disease The John Curtin School of Medical Research, The Australian National University Canberra ACT Australia.
Kanta SubbaraoDepartment of Microbiology and Immunology The University of Melbourne Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
Trent P MunroSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Paul R YoungSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.
Keith J ChappellSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD Australia.ORCID https://orcid.org/0000-0001-8636-5067
The University of Queensland · AUCSIRO Manufacturing · AUThe University of Melbourne · AUViroclinics Biosciences (Netherlands) · NLAustralian National University · AUPeter Doherty Institute · AUUtrecht University · NL
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEfforts to develop and deploy effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue at pace. Here, we describe rational antigen design through to manufacturability and vaccine efficacy of a prefusion-stabilised spike (S) protein, Sclamp, in combination with the licensed adjuvant MF59 'MF59C.1' (Seqirus, Parkville, Australia).
methodsA panel recombinant Sclamp proteins were produced in Chinese hamster ovary and screened
resultsIn mice, the Sclamp vaccine elicits high levels of neutralising antibodies, as well as broadly reactive and polyfunctional S-specific CD4
conclusionThe SARS-CoV-2 Sclamp vaccine candidate is compatible with large-scale commercial manufacture, stable at 2-8°C. When formulated with MF59 adjuvant, it elicits neutralising antibodies and T-cell responses and provides protection in animal challenge models.
Indexed as
Molecular Clampneutralising antibodiespolyfunctional T cellsrapid responseSARS‐CoV‐2subunit vaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.